P01BA02 hydroxychloroquine
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ›ANTIPROTOZOALS ›ANTIMALARIALS ›Aminoquinolines
健保收載品項 TFDA 在效許可證 12 FDA 已核准
台灣藥品與外觀
健保收載品名:"信東"瘡寧膜衣錠 200 毫克、"信隆" 免疫利 膜衣錠200毫克、"健亞" 殲瘧膜衣錠200毫克(硫酸羥氯奎寧)、"強生"倍立安膜衣錠200毫克、"應元"力昇膜衣錠 200 毫克、"衛達"克樂貴 膜衣錠 200 毫克、〝元宙〞氯?寧膜衣錠 200 毫克、必賴克/膜衣錠、必賴克?膜衣錠200毫克
無外觀照
硫酸羥氯喹
無外觀照
硫酸羥氯喹
無外觀照
安寧硫酸鹽
資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。
適應症
台灣 TFDA 核准適應症
- 圓盤狀及全身性紅斑性狼瘡、慢性多型日光疹、慢性風濕性關節炎、鎌狀瘧原蟲和間日瘧原蟲引起的瘧疾。
- 圓盤狀及全身性紅斑性狼瘡、慢性多形日光疹、慢性風濕性關節炎、鎌狀瘧原蟲和間日瘧原蟲引起之瘧疾。
- 圓盤狀及全身性紅斑性狼瘡、慢性多形日光疹、慢性風濕性關節炎、鐮狀瘧原蟲和間日瘧原蟲引起之瘧疾。
- 圓盤狀及全身性紅斑性狼瘡、慢性多形日光疹、慢性風濕性關節鹽、鏈狀瘧原蟲和間日瘧原蟲引起之瘧疾。
- 抗瘧藥、抗風濕藥、紅斑性狼瘡抑制劑。
美國 FDA 適應症(英文原文對照)
1 INDICATIONS AND USAGE Hydroxychloroquine sulfate tablets are an antimalarial and antirheumatic indicated for the: • Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale , and Plasmodium vivax in adult and pediatric patients. ( 1.1 ) • Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. ( 1.1 ) • Treatment of rheumatoid arthritis in adults. ( 1.2 ) • Treatment of systemic lupus erythematosus in adults. ( 1.3 ) • Treatment of chronic discoid lupus erythematosus in adults. ( 1.4 ) Limitations of Use ( 1.1 ): Hydroxychloroquine sulfate tablets are not recommended for the: • Treatment of complicated malaria. • Treatment of chloroquine or hydroxychloroquine-resistant strains of Plasmodium species. • Treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. • Prophylaxis of malaria in geographic areas where chloroquine resistance occurs. • Prevention of relapses of P. vivax or P. ovale because it is not active against the hypnozoite liver stage forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline drug is necessary. 1.1 Malaria Hydroxychloroquine sulfate tablets are indicated in adult and pediatric patients for the: • Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax , and Plasmodium ovale . • Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use: Hydroxychloroquine sulfate tablets are not recommended for: • Treatment of complicated malaria. • Treatment of malaria by chloroquine or hydroxychloroquine-resistant strains of Plasmodium species [see Microbiology (12.4) ]. • Treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. • Prophylaxis of malaria in geographic areas where chloroquine resistance occurs. • Prevention of relapses of P. vivax or P. ovale because it is not active against the hypnozoite liver stage forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline drug is necessary [see Microbiology (12.4) ]. For the most current information about drug resistance, refer to the latest recommendations from the Center for Disease Control and Prevention 1 . 1.2 Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. 1.3 Systemic Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of systemic lupus erythematosus in adults. 1.4 Chronic Discoid Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus in adults.
資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。
健保給付規定
查無健保特殊給付規定條款;本藥品依一般健保藥品支付規定給付。
實證補充
本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。
台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-06-09)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。